Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Jakob Liermann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1445-1940; OpenAlex author ID A5019737145. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 18

  1. Superior tumor cell killing by oxygen ion beam irradiation compared to carbon ions and photons in pancreatic Cancer cells - An in vitro investigation. Co-author DOI 10.1016/j.ctro.2026.101225↗
  2. Carbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268). Co-author DOI 10.1016/j.radonc.2026.111836↗
  3. Investigating LETd optimization strategies in carbon ion radiotherapy for pancreatic cancer: a dosimetric study using an anthropomorphic phantom. Co-author DOI 10.1002/mp.17569↗
  4. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  5. Dose assessment in moving targets and organs at risk during carbon ion therapy for pancreatic cancer with respiratory gating. Co-author DOI 10.1016/j.phro.2025.100775↗
  6. Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro. Last author DOI 10.3390/cancers16081497↗
  7. Carbon-ion radiotherapy (CIRT) as treatment of pancreatic cancer at HIT: initial radiation plan analysis of the prospective phase II PACK-study. Co-author DOI 10.1016/j.radonc.2023.109872↗
  8. A phantom to simulate organ motion and its effect on dose distribution in carbon ion therapy for pancreatic cancer. Co-author DOI 10.1088/1361-6560/ad0902↗
  9. Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer. Co-author DOI 10.1007/s00066-021-01827-9↗
  10. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial. Co-author DOI 10.1016/j.ctro.2022.03.003↗
  11. Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.708884↗
  12. Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer. Co-author DOI 10.3390/cancers13040796↗
  13. Carbon ion radiotherapy in pancreatic cancer: A review of clinical data. Co-author DOI 10.1016/j.radonc.2020.05.012↗
  14. Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000746↗
  15. Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study. Co-author DOI 10.1186/s12885-020-07434-8↗
  16. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation. Co-author DOI 10.3390/cancers11111655↗
  17. Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. First author DOI 10.1371/journal.pone.0180940↗
  18. Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro. Co-author DOI 10.1515/raon-2017-0048↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jürgen Debus · 13 shared papers, 2017–2026 · strength 2.06
  2. Patrick Naumann · 11 shared papers, 2017–2026 · strength 1.51
  3. Klaus K Herfarth · 8 shared papers, 2020–2026 · strength 1.33
  4. Andrea Mairani · 4 shared papers, 2023–2026 · strength 0.88
  5. Christina Stengl · 3 shared papers, 2023–2025 · strength 0.68
  6. Filipa Baltazar · 3 shared papers, 2023–2026 · strength 0.67
  7. Edgar Ben‐Josef · 3 shared papers, 2020–2022 · strength 0.42
  8. José Vedelago · 2 shared papers, 2023–2025 · strength 0.41
  9. Oliver Jäkel · 2 shared papers, 2023–2025 · strength 0.41
  10. Juergen Debus · 2 shared papers, 2022–2023 · strength 0.36
  11. Manuel Röhrich · 2 shared papers, 2021–2026 · strength 0.34
  12. Peter Ernst Huber · 1 shared paper, 2026 · strength 0.26
  13. Jonathan M. Schneeweiss · 1 shared paper, 2026 · strength 0.26
  14. Lixin Mai · 1 shared paper, 2026 · strength 0.26
  15. Albert C. Koong · 1 shared paper, 2025 · strength 0.23
  16. Alexander Dean Sherry · 1 shared paper, 2025 · strength 0.23
  17. Enoch Chang · 1 shared paper, 2025 · strength 0.23
  18. Todd Anthony Aguilera · 1 shared paper, 2025 · strength 0.23
  19. Chad Z. Tang · 1 shared paper, 2025 · strength 0.23
  20. Ethan Bernard Ludmir · 1 shared paper, 2025 · strength 0.23
  21. Eugene Jon Koay · 1 shared paper, 2025 · strength 0.23
  22. Shubham Pant · 1 shared paper, 2025 · strength 0.23
  23. Ching-Wei David Tzeng · 1 shared paper, 2025 · strength 0.23
  24. Christoph Michalski · 1 shared paper, 2026 · strength 0.23
  25. Semi Harrabi · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.